Annexon, Inc. Q2 2026: Net loss $55.3M — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Annexon, Inc. reported a net loss of $55.3M for Q2 2026, widening from $49.2M in the prior year period, with no product revenue generated. The company highlighted clinical progress on Tanruprubart (Phase 3 GBS), expanded Vonaprument Phase 3 endpoints, and completed dosing for ANX1502. Operational readiness increased via contract manufacturing for vonaprument technology transfer.
Annexon, Inc. reported a net loss of $55.3M for the second quarter of 2026 and did not report product revenue for the period as it has not yet generated revenue from product sales.
Financial Highlights
- Revenue: Not reported for the quarter (no product revenue; the company states it has not generated any revenue from product sales).
- Net income: Net loss of $55.3M for Q2 2026, compared with a net loss of $49.2M in Q2 2025.
- Diluted EPS: Not provided (diluted EPS not disclosed in Part I Items 1–2 of this 10‑Q).
Business Highlights
- Clinical progress: Tanruprubart Phase 3 showed rapid, sustained improvement in Guillain‑Barré syndrome (GBS); a Marketing Authorization Application was filed with the EMA and the company plans FDA engagement ahead of a BLA submission in Q4 2026.
- Late‑stage program expansion: Vonaprument Phase 3 ARCHER II added a Month‑24 dual primary endpoint and an open‑label extension to assess longer‑term vision protection.
- POC and formulation work: ANX1502 oral program completed CAD dosing achieving target drug levels; an enteric‑coated tablet is under evaluation with a proof‑of‑concept update expected in H2 2026.
- Operational readiness: Increased contract manufacturing activity to support vonaprument technology transfer to a commercial‑ready facility and continued global trial execution with low discontinuation rates.
Original SEC Filing: Annexon, Inc. [ ANNX ] - 10-Q - Aug. 12, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.